Terminated PHASE3 INTERVENTIONAL 1-arm NCT02524847

Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Participants With Steroid Refractory Acute Graft Versus Host Disease

Single-Arm Study to Assess the Efficacy of UVADEX® (Methoxsalen) Sterile Solution in Conjunction With the THERAKOS® CELLEX® Photopheresis System in Pediatric Patients With Steroid-Refractory Acute Graft-vs-Host Disease (aGvHD)

Sponsor: Therakos, Inc., a Mallinckrodt Company

Conditions Steroid Refractory Acute Graft Versus Host Disease

Interventions Extracorporeal Photopheresis (ECP) Methoxsalen

Updated 18 times since 2017 Last updated: Aug 24, 2020 Started: Jan 20, 2016 Primary completion: Jul 16, 2019 Completion: Jul 16, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow enrollment

Listed as NCT02524847, this PHASE3 trial focuses on Steroid Refractory Acute Graft Versus Host Disease and remains terminated or withdrawn. Sponsored by Therakos, Inc., a Mallinckrodt Company, it has been updated 18 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

18 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE3

▶ Show 13 earlier versions

Oct 2020 — Jan 2021 [monthly]

Terminated PHASE3
May 2020 — Oct 2020 [monthly]

Terminated PHASE3

Status: Completed → Terminated
Nov 2019 — May 2020 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
May 2019 — Nov 2019 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Jan 2019 — May 2019 [monthly]

Recruiting PHASE3
Dec 2018 — Jan 2019 [monthly]

Recruiting PHASE3
Sep 2018 — Dec 2018 [monthly]

Recruiting PHASE3
Jun 2018 — Sep 2018 [monthly]

Recruiting PHASE3
May 2018 — Jun 2018 [monthly]

Recruiting PHASE3
Oct 2017 — May 2018 [monthly]

Recruiting PHASE3
Sep 2017 — Oct 2017 [monthly]

Recruiting PHASE3
Feb 2017 — Sep 2017 [monthly]

Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE3

First recorded

Jan 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Therakos, Inc., a Mallinckrodt Company

Data source: Mallinckrodt

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Barcelona, Spain , Boston, United States , Budapest, Hungary , Chicago, United States , Cleveland, United States , Hackensack, United States , Houston, United States , Leipzig, Germany , Los Angeles, United States and 20 more locations